Skip to main
ITOS
ITOS logo

ITOS Stock Forecast & Price Target

ITOS Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 13%
Buy 38%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

ITeos Therapeutics Inc's current pipeline, featuring innovative product candidates such as EOS-850 and EOS-448, positions the company favorably within the biopharmaceutical sector, as these candidates target critical mechanisms in cancer treatment. The promising efficacy results from ongoing studies, particularly the reported 66% overall response rate in patients treated with the combination therapy of belantamab and dostarlimab, underscore the potential for improved clinical outcomes, which could enhance investor confidence. Moreover, the implementation of updated safety protocols in the Phase 3 studies may ultimately lead to reduced discontinuation rates and improved overall survival benefits, further strengthening the company’s growth outlook.

Bears say

ITeos Therapeutics Inc. reported no revenue in the fourth quarter of 2024, reflecting the company's ongoing challenges in generating income from its product candidates. The net loss of $1.01 per share was slightly better than the consensus estimate of a loss of $1.03 per share, but the lack of revenue raises concerns about the company's financial viability and ability to cover operating expenses. Additionally, the absence of revenue highlights significant risks related to the commercialization of its innovative therapies in a competitive biopharmaceutical landscape.

ITOS has been analyzed by 8 analysts, with a consensus rating of Buy. 13% of analysts recommend a Strong Buy, 38% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of iTeos Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About iTeos Therapeutics, Inc. (ITOS) Forecast

Analysts have given ITOS a Buy based on their latest research and market trends.

According to 8 analysts, ITOS has a Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

iTeos Therapeutics, Inc. (ITOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.